# Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

> **NCT04688151** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 22 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma (PCNSL)

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04688151
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-22
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04688151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04688151, "Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04688151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*